AR028611A1 - Sistema terapcutico transcutrneo con reduccion de la tendencia a la cristalizacinn de sustancia activa - Google Patents

Sistema terapcutico transcutrneo con reduccion de la tendencia a la cristalizacinn de sustancia activa

Info

Publication number
AR028611A1
AR028611A1 ARP010102443A ARP010102443A AR028611A1 AR 028611 A1 AR028611 A1 AR 028611A1 AR P010102443 A ARP010102443 A AR P010102443A AR P010102443 A ARP010102443 A AR P010102443A AR 028611 A1 AR028611 A1 AR 028611A1
Authority
AR
Argentina
Prior art keywords
active substance
crystallization
transcutrene
therapcutic
trend
Prior art date
Application number
ARP010102443A
Other languages
English (en)
Inventor
Robert-Peter Klein
Reinhold Meconi
Frank Seibertz
Original Assignee
Lohmann Therapie Syst Lts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lohmann Therapie Syst Lts filed Critical Lohmann Therapie Syst Lts
Publication of AR028611A1 publication Critical patent/AR028611A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un sistema terapéutico transcutáneo en forma de parche para la cesion controlada de sustancias activas a la piel humana o animal, en que el sistema tiene una capa posterior, un deposito de sustancia activa unido a ella y una capa protectora desprendible, caracterizado por poseer el deposito que contiene la sustancia activa como componentes principales al menos un agente filmogeno y al menos un polímero que impida o suprima la cristalizacion de la(s) sustancia(s) activa(s).
ARP010102443A 2000-05-25 2001-05-23 Sistema terapcutico transcutrneo con reduccion de la tendencia a la cristalizacinn de sustancia activa AR028611A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10025971A DE10025971B4 (de) 2000-05-25 2000-05-25 Transdermales therapeutisches System in Plasterform mit verminderter Tendenz zur Wirkstoffkristallisation und seine Verwendung

Publications (1)

Publication Number Publication Date
AR028611A1 true AR028611A1 (es) 2003-05-14

Family

ID=7643564

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102443A AR028611A1 (es) 2000-05-25 2001-05-23 Sistema terapcutico transcutrneo con reduccion de la tendencia a la cristalizacinn de sustancia activa

Country Status (9)

Country Link
US (1) US20030175330A1 (es)
EP (1) EP1283705A1 (es)
JP (1) JP2003534271A (es)
KR (1) KR20030001556A (es)
AR (1) AR028611A1 (es)
AU (1) AU2001265949A1 (es)
CA (1) CA2410336A1 (es)
DE (1) DE10025971B4 (es)
WO (1) WO2001089487A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10211832A1 (de) * 2002-03-16 2003-10-02 Lohmann Therapie Syst Lts Hormonhaltiges transdermales therapeutisches System mit einem Wirkstoffreservoir auf der Basis von Vinylacetat-Vinylpyrrolidon-Copolymer mit verbesserter Kohäsion
DE10304988A1 (de) * 2003-02-07 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System mit verbessertem Hautklebeverhalten
PT1613297E (pt) * 2003-04-14 2007-08-23 Lohmann Therapie Syst Lts Emplastro terapêutico com matriz de polissiloxano compreendendo capsaicina

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4624665A (en) * 1984-10-01 1986-11-25 Biotek, Inc. Method of transdermal drug delivery
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE3933460A1 (de) * 1989-10-06 1991-04-18 Lohmann Therapie Syst Lts Oestrogenhaltiges wirkstoffpflaster
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
FR2699406B1 (fr) * 1992-12-21 1995-03-10 Commissariat Energie Atomique Films à base de copolymères, leurs applications dans des systèmes transdermiques et leurs procédés de préparation.
DE69401945T3 (de) * 1993-06-25 2004-09-02 Alza Corp., Palo Alto Einarbeitung eines poly-n-vinylamids in ein transdermales system
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
DE19500662C2 (de) * 1995-01-12 2001-04-26 Lohmann Therapie Syst Lts Estradiolhaltiges Pflaster und seine Verwendung
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
US5928666A (en) * 1996-11-12 1999-07-27 Cygnus Inc. Crystalline form of estradiol and pharmaceutical formulations comprising same
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
DE19828274C2 (de) * 1998-06-25 2002-11-28 Rottapharm Bv Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
DE19830651A1 (de) * 1998-07-09 2000-01-13 Lohmann Therapie Syst Lts Steroidhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
US20020004065A1 (en) * 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents

Also Published As

Publication number Publication date
US20030175330A1 (en) 2003-09-18
CA2410336A1 (en) 2001-11-29
AU2001265949A1 (en) 2001-12-03
WO2001089487A1 (de) 2001-11-29
DE10025971A1 (de) 2001-12-06
EP1283705A1 (de) 2003-02-19
DE10025971B4 (de) 2004-09-02
KR20030001556A (ko) 2003-01-06
JP2003534271A (ja) 2003-11-18

Similar Documents

Publication Publication Date Title
ES2557988T3 (es) Método para tratar enfermedades de próstata basado en el suministro local de principios activos
ES2148838T3 (es) Oligonucleotidos antisentido contra la subunidad reguladora alfa de la proteina quinasa dependiente de camp para el tratamiento del cancer.
DE602005011105D1 (de) Implantierbare arzneiabgabevorrichtung mit drahtfäden
NZ707377A (en) Combination therapy methods for treating proliferative diseases
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
AR056806A1 (es) Moleculas quimericas de anticuerpo rankl- pth/ pthrp
MX2009010000A (es) Dispositivo para el suministro de farmaco.
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
AR051446A1 (es) Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
CO6491121A2 (es) Semillas para braquiterapia con matriz de rapida disolucion para un optimo suministro de radionucleidos a tejido canceroso
AR033418A1 (es) Preparado farmaceutico mucoadhesivo desintegrable para la administracion de sustancia activa en medicina veterinaria y humana
ATE429908T1 (de) Hormonhaltiges transdermales therapeutisches system mit einem wirkstoffreservoir auf der basis von vinylacetat-vinylpyrrolidon-copolymer mit verbesserter kohäsion.
WO2004012676A3 (en) Drug-loaded biological material chemically treated with genipin
EA200600921A1 (ru) Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
BR112021017878A2 (pt) Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação
DK1140198T3 (da) Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
AR034493A1 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
BR112012014107B8 (pt) sistema terapêutico transdérmico (tts) e processo de produção de tts
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
AR095416A1 (es) Tratamiento con cutirsen que presenta una toxicidad reducida
AR028611A1 (es) Sistema terapcutico transcutrneo con reduccion de la tendencia a la cristalizacinn de sustancia activa
FR2872702B3 (fr) Systeme de delivrance
ATE499378T1 (de) Anthracyclinderivate
BR112021025291A2 (pt) Dispositivos de contenção de medicamento e composições associadas

Legal Events

Date Code Title Description
FB Suspension of granting procedure